{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-040982","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.865808+00:00","generated_at":"2026-05-31T02:45:25.271883+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ChromaDex appoints Ozan Pamir as CFO effective October 21, 2024; James Lee returns to Controller role","bullets":["Ozan Pamir named CFO effective Oct 21; succeeds interim CFO James Lee who remains Controller.","Annual base salary of $400,000; target bonus 50% of base; option grant with initial value of $360,000.","Pamir previously CFO of 180 Life Sciences; also held investment banking roles at Ventum Financial.","Option vests: 1/3 one-year anniversary, rest over 24 months; severance: 9 months' base salary on termination without cause."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-040982","json":"https://secwatch.observer/filing/0001628280-24-040982.json","markdown":"https://secwatch.observer/filing/0001628280-24-040982.md","text":"https://secwatch.observer/filing/0001628280-24-040982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/0001628280-24-040982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/cdxc-20240919.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:45:25.271883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93a8c2c17a","claim":"Ozan Pamir was appointed as Chief Financial Officer and Principal Accounting Officer at Niagen Bioscience, Inc..","evidence_excerpt":"On September 19, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed Ozan Pamir as the Company’s Chief Financial Officer and Principal Accounting Officer, effective as of October 21, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/0001628280-24-040982-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"b0825339e7","claim":"James Lee changed role as Controller at Niagen Bioscience, Inc..","evidence_excerpt":"Mr. Pamir will replace James Lee, who is currently serving as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/0001628280-24-040982-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"replaced"},{"label":"Role","value":"Controller"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}